Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 1/20 | 0.49 |
| ▸ | PLD2 | O14939 | 16/20 | 0.47 |
| ▸ | PLD1 | Q13393 | 16/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.45 |
| ▸ | YEATS4 | O95619 | 1/20 | 0.41 |
| ▸ | MLLT3 | P42568 | 1/20 | 0.41 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | YEATS2 | Q9ULM3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5000728 | 0.86 | OPRL1 (0.58) | OPRL1PLD2PLD1ADRA1DADRA1A | |
| SCHEMBL5006669 | 0.85 | OPRL1 (0.59) | OPRL1PLD2PLD1ADRA1DADRA1A | |
| SCHEMBL5000769 | 0.85 | OPRL1 (0.59) | OPRL1PLD2PLD1ADRA1DADRA1A | |
| SCHEMBL4444656 | 0.85 | OPRL1 (0.49) | OPRL1PLD2PLD1ADRA1DADRA1A | |
| SCHEMBL4445747 | 0.84 | PLD2 (0.43) | PLD2PLD1 | |
| SCHEMBL4444318 | 0.83 | OPRL1 (0.48) | OPRL1PLD2PLD1ADRA1DADRA1A | |
| SCHEMBL4997384 | 0.83 | PLD2 (0.49) | OPRL1PLD2PLD1ADRA1DADRA1A | |
| SCHEMBL4440705 | 0.79 | YEATS4 (0.65) | PLD2PLD1ADRA1DADRA1AADRA1B | |
| SCHEMBL4440106 | 0.78 | YEATS4 (0.56) | PLD2PLD1ADRA1DADRA1AADRA1B | |
| SCHEMBL4434580 | 0.77 | PLD2 (0.47) | PLD2PLD1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121656-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | Pfizer Products Inc. (US) | 2009-11-25 | — | — | EP | claimed |
| US-20080287479-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER INC | 2008-11-20 | — | — | US | claimed |
| WO-2008084300-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER PRODUCTS INC. (US) | 2008-07-17 | — | — | WO | claimed |
| EP-2121656-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | Pfizer Products Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080287479-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER INC | 2008-11-20 | — | — | US | disclosed |
| WO-2008084300-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER PRODUCTS INC. (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287479-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | SPTLC1, SPTLC2, CPT1A | OPRL1 2087/4885PLD2 917/4885PLD1 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.